A winning strategy
Thomson Reuters' retrospective industry report 2013 says that although pipelines are experiencing relatively fewer early-stage successes, the success of late-stage drugs is increasing, a balance which researchers attribute to the pharmaceutical industry being able to “fail fast, fail cheaply” since early failures provide less financial drag. This observation contributed to the strategy for mergers that make pipeline sense.1
Why target mitochondria to derisk
your pipeline early?
ICDD offers services at the pre-clinical and early clinical stages to derisk your pipeline using the mitochondria as a target. Previously undetected mitochondrial liabilities are the main cause of failure at late clinical stage and post-marketing.2 ICDD’s technologies have been around since 2007 and have been largely validated in the biotech, mid-, and large pharma settings. Return on investment gained by our clients can now be calculated as drugs selected and de-selected through our platforms are being marketed. Typical ROI for using the Cellesis toxicity profile is 37.3 fold. Another 12.3 fold ROI is obtained post-launch when using our tools to position the marketed product with respect to its competition.
1. Debohrah Weinstein, Medical Marketing and Media. Sept 08, 2014.
2. Dykens & Will, DDT 12: 777-785, 2007.
Which technology to use
Cellesis toxicity profiler
Use ICDD's Cellesis toxicity profiler to anticipate clinical tolerance at an early preclinical stage. The Cellesis profiler has been validated by the DSEC and is in use in the pharmaceutical industry since 2009.
The Cellesis toxicity profiler examines mitochondrial behavior and mitochondrial fusion/fission balance. It uses the simultaneous measure of 48 variables along four dimensions:
- Mitochondrial reticular network organization
- Mitochondrial membrane permeability
We can also rank order compounds within a large database of reference compounds with known tolerance profiles and compare them to their nearest neighbour.
Organ toxicity signatures can be searched upon request.
Integrate knowledge of individual tolerance & response with the co-development of companion diagnostic using our cellulomic and proteomic platforms. This option is only available through industrial partnering.
BBS or BBS+ package
Our Bioenergetic Balance Screen (BBS/BBS+), available in HTS/dose response studies, can be used as an early indicator of mitochondrial liability.
The BBS/BBS+ packages are the multiplexed and integrated measurements, in a same cell, of:
- Oxygen consumption
- ATP production
- Glycolysis level
- Cell viability
- TCA cycle turning (BBS+ only)